MGX

Metagenomi Therapeutics, Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001785279 Biotech & Drug Discovery

$0.7670 −0.04 (−4.84%)

Oct 26 4:00 PM ET · prev $0.8060

Market cap

$30.8M

Nano cap

Consensus

Buy

78% Buy or better · 9 analysts

Median target

$7.00

+813% · range $5.00–9.00

Next earnings

Nov 18

in 23 days · EPS est. −$0.62

1 year

−72.0%

from $2.74 · Oct 27

30 days

−32.7%

from $1.14

52-week range

$0.7670–2.74

at the low

Avg volume 20D

167.6K

shares / day

Short interest

🔒 Subscribers only

Insider net

+$3.1K

1 buyer · 3 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BEARISH 2 reports · 90 days

Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score

Avg score

·High conf. 1/2 ·Next Earnings date, Nov 18, 2026

Strongest NEUTRAL Metagenomi Therapeutics filed a September 2026 corporate presentation under Item 7.01, highlighting its lead…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Feb 28 Three major passive institutional investors — Morgan Stanley, Wells…
S Mar 5 3 insiders sell $5.9K at $1.60
R Mar 5 Metagenomi Therapeutics (MGX) reported its full-year 2025 financial…
R May 11 Metagenomi reported Q1 2026 EPS of -$0.61, missing consensus of -$0.…
S Jun 5 3 insiders sell $9.3K at $1.30
S Sep 8 3 insiders sell $5.1K at $1.16
B Sep 9 1 insider buy $23.4K at $1.17

Signal stack

Where each data set points today.

InsidersMIXED

1 insider bought $23.4K at an average $1.17. 3 insiders sold $20.3K. Price is 34% below their cost.
InstitutionsBEARISH

Q2 2026: 2 added (0 new), 8 trimmed or exited.
AnalystsBULLISH

7 of 9 rate it Buy or better. Every target is above the price.
EstimatesFALLING

Current-quarter EPS estimate −$0.503 → −$0.618 over 90 days. 0 up, 3 down in 30 days.
TrendDOWNTREND

29% below its 50-day average. New closing low $0.7670 on Oct 26.
SocialQUIET

No Reddit mentions this week. Last mention Oct 19.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
WELLS FARGO & COMPANY/MN	ADD	379,508	$451.6K
JACOBS LEVY EQUITY MANAGEMENT, INC	TRIM	160,000	$190.4K
MILLENNIUM MANAGEMENT LLC	TRIM	114,025	$135.7K
Man Group plc	ADD	109,130	$129.9K
JANE STREET GROUP, LLC	TRIM	38,396	$45.7K
MORGAN STANLEY	NEAR_EXIT	5,302	$6.3K
OSAIC HOLDINGS, INC.	TRIM	1,891	$2.3K
FMR LLC	NEAR_EXIT	588	$700.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts

Buy 78% rate it Buy or better

Strong Buy2Buy5Hold2Sell0Strong Sell0

12-month targets · 3 analysts

$0.7670 $5.00 $7.00 $9.00

Price is below the lowest target. Median implies +813%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 11, 2026	Wells Fargo MAINTAIN	MAINTAIN	Overweight
Jul 7, 2026	Chardan Capital MAINTAIN	MAINTAIN	Buy
May 12, 2026	Wells Fargo MAINTAIN	MAINTAIN	Overweight

Insider ledger

Form 4

$23.4K

bought · 1 insider

$20.3K

sold · 3 insiders

−34.4%

vs their $1.17 cost

Date	Insider	Type	Value
Sep 9, 2026	Reid Laurence Director	BUY	$23.3K
Sep 9, 2026	Reid Laurence Director	BUY	$138.06
Sep 8, 2026	Wapnick Pamela Chief Financial Officer	SELL	$2.2K
Sep 8, 2026	Irish Jian See Remarks	SELL	$2.5K
Sep 8, 2026	Wein Matthew See Remarks	SELL	$414.71
Jun 9, 2026	Eckhardt Juergen Director	AWARD	21,000 sh
Jun 9, 2026	BJERKHOLT ERIC Director	AWARD	21,000 sh
Jun 9, 2026	Dere Willard H Director	AWARD	21,000 sh

Earnings setup

Estimates

Nov 18

reports in 23 days

−$0.62

EPS estimate, this quarter

−23%

estimate change, 90 days

0↑ 3↓

revisions, 30 days

Current-quarter EPS estimate

−$0.503

90d

−$0.618

60d

−$0.618

30d

−$0.618

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.62	-$0.75–-$0.55	+0.0%	$2.1M
Next Q	-$0.52	-$0.61–-$0.33	+0.0%	$2.1M
Current FY	-$2.42	-$2.53–-$2.16	+0.0%	$5.1M
Next FY	-$1.83	-$2.30–-$1.56	+0.0%	$7.5M